MESALAZINE - AN OVERVIEW OF KEY PRECLINICAL STUDIES

被引:29
作者
BILYARD, KG [1 ]
JOSEPH, EC [1 ]
METCALF, R [1 ]
机构
[1] SK&F RES LTD,WELWYN GARDEN CIT,HERTS,ENGLAND
关键词
Keratoconjunctivitis sicca; Nephrotoxicity; Ocular lesions; Pharmacokinetics; Renal papillary necrosis;
D O I
10.3109/00365529009091911
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Studies were undertaken to evaluate the clinical relevance of toxicologic assessments of mesalazine and to establish mesalazine pharmacokinetics. In the toxicology studies groups of rats and dogs received various doses of mesalazine, ranging from 40 to 320 mg/kg of body weight, for 6 or 12 months. Evidence of renal papillary necrosis was found at 60 or 100 mg/kg in dogs and 320 mg/kg in rats. Data are presented to show that drug absorption after the clinical doses of mesalazine given to human patients is much lower than after the potentially nephrotoxic doses given to experimental animals. In the pharmacokinetic studies plasma from rats and dogs given various doses of mesalazine was analysed for mesalazine and its major metabolites. The results demonstrated that mesalazine in pharmaceutic preparations is not likely to present a nephrotoxic risk to patients, given the low systemic exposure achieved. After 12 months of mesalazine administration to dogs, many showed an ocular condition diagnosed as keratoconjunctivitis sicca. Experimental and epidemiologic evidence demonstrates that this condition is peculiar to dogs, and there are no reports of untoward ocular effects in patients receiving long-term therapy with mesalazine. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:52 / 55
页数:4
相关论文
共 11 条
[1]   KERATOCONJUNCTIVITIS SICCA IN THE DOG FOLLOWING 5-AMINOSALICYLIC ACID ADMINISTRATION [J].
BARNETT, KC ;
JOSEPH, EC .
HUMAN TOXICOLOGY, 1987, 6 (05) :377-383
[2]   RENAL-FUNCTION AFTER PROLONGED CONSUMPTION OF ASPIRIN [J].
BURRY, HC ;
DIEPPE, PA .
BRITISH MEDICAL JOURNAL, 1982, 284 (6322) :1117-1118
[3]  
CHASSEAUD L, 1986, PHARMACOKINETICS MET
[4]   RENAL-FUNCTION WAS NOT IMPAIRED BY TREATMENT WITH 5-AMINOSALICYLIC ACID IN RATS AND MAN [J].
DIENER, U ;
TUCZEK, HV ;
FISCHER, C ;
MAIER, K ;
KLOTZ, U .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1984, 326 (03) :278-282
[5]  
FACCINI JM, 1982, NEPHROTOXICITY ASSES, P82
[6]   DISPOSITION OF 5-AMINOSALICYLIC ACID, THE ACTIVE METABOLITE OF SULPHASALAZINE, IN MAN [J].
FISCHER, C ;
MAIER, K ;
STUMPF, E ;
VONGAISBERG, U ;
KLOTZ, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 25 (04) :511-515
[7]  
HARDY JG, 1987, ALIMENT PHARM THERAP, V1, P263
[8]  
MCGEOWN MG, 1986, IATROGENIC DISEASES, P790
[9]  
NORLANDER B, 1989, ALIMENT PHARM THERAP, V3, P333
[10]   KERATOCONJUNCTIVITIS SICCA IN THE DOG - A REVIEW OF 200 CASES [J].
SANSOM, J ;
BARNETT, KC .
JOURNAL OF SMALL ANIMAL PRACTICE, 1985, 26 (03) :121-131